Charles River and American Heart Association Join Forces to Advance Cardiovascular Health
Cardiovascular disease (CVD) continues to pose one of the most significant public health challenges globally, affecting millions of individuals and placing a substantial burden on healthcare systems. In response to this ongoing crisis, Charles River Laboratories International, Inc. has announced a strategic collaboration with the American Heart Association (AHA), a globally recognized nonprofit organization dedicated to improving heart and brain health. This partnership aims to strengthen awareness, prevention, and community-based health initiatives, particularly at a time when cardiovascular conditions remain a leading cause of mortality.
A Shared Commitment to Health Advancement
Charles River Laboratories, known for its contributions to drug development and biomedical research, has long emphasized its corporate purpose: “Together, We Create Healthier Lives.” This collaboration with the American Heart Association aligns seamlessly with that mission, extending the company’s impact beyond laboratory research into real-world community health outcomes.
By supporting the AHA’s initiatives, Charles River is reinforcing its commitment to science-driven progress and public health education. The partnership highlights how private-sector organizations can play a vital role in addressing large-scale health challenges through collaboration, innovation, and community engagement.
Kristen Eisenhauer, Chief Commercial Officer at Charles River, emphasized the importance of such partnerships, noting that cardiovascular disease continues to have a profound impact on families and communities. She highlighted the company’s pride in supporting prevention, education, and scientific efforts that aim to improve cardiovascular health outcomes worldwide.
Supporting the “Heart of Boston” Campaign
A key component of this collaboration is Charles River’s support for the American Heart Association’s “Heart of Boston” campaign. This initiative focuses on improving cardiovascular health outcomes across Greater Boston while also contributing to nationwide efforts.
The campaign is designed to address critical health disparities, promote healthier lifestyles, and enhance access to preventive care. By targeting both local and broader populations, the initiative aims to create sustainable improvements in public health. Charles River’s involvement will help amplify these efforts, providing resources and visibility to drive meaningful change.
Through this campaign, both organizations seek to foster stronger community connections, encourage proactive health management, and empower individuals with the knowledge needed to reduce their risk of heart disease and stroke.
The Ongoing Burden of Cardiovascular Disease
The collaboration comes at a crucial moment, as highlighted by the American Heart Association’s 2026 Heart Disease and Stroke Statistics Update. Despite advancements in medical science and healthcare delivery, cardiovascular disease remains the leading cause of death in the United States.
Heart disease alone accounts for a significant proportion of mortality, while stroke has risen to become the fourth-leading cause of death. Together, these conditions are responsible for more than one in four deaths nationwide. These statistics underscore the urgent need for continued awareness, research, and preventive measures.
While there have been recent improvements in overall cardiovascular mortality—particularly following the surge in deaths associated with the COVID-19 pandemic—the data indicates that the underlying risk factors remain widespread and persistent.
Persistent Risk Factors and Health Challenges
One of the most concerning findings from the AHA’s latest report is the prevalence of key risk factors contributing to cardiovascular disease. Conditions such as high blood pressure, diabetes, and obesity continue to affect a large portion of the population.
High blood pressure, often referred to as a “silent killer,” remains one of the most significant contributors to heart disease and stroke. Many individuals are unaware of their condition, leading to delayed diagnosis and treatment. Similarly, the rising incidence of diabetes and obesity further exacerbates cardiovascular risk, creating a complex web of health challenges that require comprehensive intervention.
These persistent risk factors highlight the importance of education and early intervention. Public awareness campaigns, like those supported through this collaboration, play a critical role in helping individuals understand their health risks and take proactive steps toward prevention.
The Role of Education and Prevention
Education is a cornerstone of effective cardiovascular disease prevention. By providing individuals with accurate, accessible information about risk factors and healthy lifestyle choices, organizations like the American Heart Association empower communities to take control of their health.
Preventive measures, including regular health screenings, balanced nutrition, physical activity, and smoking cessation, can significantly reduce the risk of developing cardiovascular conditions. However, achieving widespread adoption of these practices requires sustained effort, community engagement, and supportive infrastructure.
Charles River’s support enhances the reach and impact of these educational initiatives, ensuring that more individuals have access to the resources they need to make informed health decisions.
Advancing Science and Innovation
In addition to community outreach and education, scientific research remains a critical component of combating cardiovascular disease. Charles River’s expertise in preclinical and clinical research positions it as a valuable partner in advancing scientific understanding and developing new therapies.
By aligning with the American Heart Association, the company contributes to a broader ecosystem of innovation aimed at improving diagnosis, treatment, and prevention of cardiovascular conditions. This collaboration underscores the importance of integrating research with real-world application, bridging the gap between scientific discovery and patient outcomes.
The Importance of Public-Private Partnerships
The partnership between Charles River and the American Heart Association exemplifies the power of public-private collaboration in addressing complex health challenges. By combining resources, expertise, and networks, such partnerships can achieve greater impact than individual efforts alone.
Public-private partnerships enable the scaling of initiatives, fostering innovation and ensuring that solutions reach diverse populations. They also encourage the sharing of knowledge and best practices, accelerating progress in the fight against cardiovascular disease.
This collaboration serves as a model for how organizations across sectors can work together to create meaningful change in public health.
Addressing Health Equity and Community Impact
A critical aspect of improving cardiovascular health is addressing disparities in access to care and health outcomes. Certain populations, including underserved and marginalized communities, often face higher risks and limited access to preventive services.
The “Heart of Boston” campaign and similar initiatives aim to address these disparities by focusing on community-specific needs and promoting equitable access to healthcare resources. By supporting these efforts, Charles River helps ensure that advancements in cardiovascular health benefit all individuals, regardless of socioeconomic status or geographic location.
Community engagement plays a vital role in this process, fostering trust and encouraging participation in health programs. Through outreach and collaboration with local organizations, the partnership seeks to create lasting improvements in community health.
Looking Ahead: Sustaining Progress in Cardiovascular Health
While progress has been made in reducing cardiovascular mortality, the journey toward improved heart health is far from complete. The persistence of risk factors and the evolving nature of public health challenges require ongoing commitment and innovation.
The collaboration between Charles River and the American Heart Association represents a proactive step toward sustaining and accelerating progress. By focusing on prevention, education, research, and community engagement, the partnership addresses multiple facets of cardiovascular health.
Looking ahead, continued investment in these areas will be essential to achieving long-term improvements. Efforts to integrate technology, expand access to care, and promote healthy behaviors will play a crucial role in shaping the future of cardiovascular health.
The collaboration between Charles River Laboratories and the American Heart Association highlights the importance of collective action in addressing one of the world’s most pressing health challenges. By supporting initiatives that promote awareness, prevention, and scientific advancement, the partnership aims to reduce the burden of cardiovascular disease and improve quality of life for individuals and communities.
As cardiovascular disease continues to impact millions, initiatives like this serve as a reminder that progress is possible through collaboration, innovation, and a shared commitment to health. With sustained effort and strategic partnerships, the vision of healthier hearts and longer lives can become a reality for future generations.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them
